Do analysts prefer BFRI or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, BFRI or GELS?

Gelteq has lower revenue, but higher earnings than Biofrontera. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biofrontera $41.71M 0.57 -$10.54M -$0.45 N/A Gelteq $110K 87.63 -$4.30M N/A N/A

Is BFRI or GELS more profitable?

Gelteq has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Gelteq's return on equity of 0.00% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets Biofrontera -13.78% -145.81% -31.30% Gelteq N/A N/A N/A

Do analysts prefer GELS or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, GELS or ABVC?

Gelteq has higher earnings, but lower revenue than ABVC BioPharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 87.63 -$4.30M N/A N/A ABVC BioPharma $510K 50.17 -$7.91M -$0.30 N/A

Is GELS or ABVC more profitable?

Gelteq's return on equity of 0.00% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A ABVC BioPharma N/A -47.68% -30.97%

Does the media prefer GELS or ABVC?

In the previous week, Gelteq and Gelteq both had 1 articles in the media. Gelteq's average media sentiment score of 0.00 equaled ABVC BioPharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gelteq 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GELS or COCP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, GELS or COCP?

Gelteq has higher revenue and earnings than Cocrystal Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 87.63 -$4.30M N/A N/A Cocrystal Pharma N/A N/A -$8.83M -$0.76 N/A

Is GELS or COCP more profitable?

Gelteq's return on equity of 0.00% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A Cocrystal Pharma N/A -207.47% -123.33%

Do analysts rate GELS or PSTV?

Plus Therapeutics has a consensus price target of $51.75, indicating a potential upside of 1,778.40%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better earnings and valuation, GELS or PSTV?

Gelteq has higher revenue and earnings than Plus Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 87.63 -$4.30M N/A N/A Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A

Does the media prefer GELS or PSTV?

In the previous week, Gelteq and Gelteq both had 1 articles in the media. Gelteq's average media sentiment score of 0.00 equaled Plus Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gelteq 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GELS or ?

Given 's higher probable upside, analysts plainly believe is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, GELS or ?

has lower revenue, but higher earnings than Gelteq. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 87.63 -$4.30M N/A N/A N/A N/A N/A N/A N/A

Is GELS or more profitable?

Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A N/A N/A N/A

Does the media refer more to GELS or ?

In the previous week, had 1423 more articles in the media than Gelteq. MarketBeat recorded 1424 mentions for and 1 mentions for Gelteq. Gelteq's average media sentiment score of 0.00 equaled 'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gelteq 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 347 Very Positive mention(s) 336 Positive mention(s) 333 Neutral mention(s) 271 Negative mention(s) 137 Very Negative mention(s) Neutral

Gelteq (GELS) Competitors

$0.90 +0.01 (+0.76%)

As of 09/4/2026 04:00 PM Eastern

Compare

GELS vs. BFRI, ABVC, COCP, PSTV, and VYNE

Should you buy Gelteq stock or one of its competitors? Gelteq's main competitors and comparable companies include Biofrontera (BFRI), ABVC BioPharma (ABVC), Cocrystal Pharma (COCP), Plus Therapeutics (PSTV), and VYNE Therapeutics (VYNE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Gelteq compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Gelteq has lower revenue, but higher earnings than Biofrontera.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.57	-$10.54M	-$0.45	N/A
Gelteq	$110K	87.63	-$4.30M	N/A	N/A

Biofrontera has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.41, suggesting that its share price is 141% less volatile than the broader market.

In the previous week, Gelteq had 1 more articles in the media than Biofrontera. MarketBeat recorded 1 mentions for Gelteq and 0 mentions for Biofrontera. Biofrontera's average media sentiment score of 0.00 equaled Gelteq'saverage media sentiment score.

Company	Overall Sentiment
Biofrontera	Neutral
Gelteq	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.1% of Biofrontera shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Gelteq has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Gelteq's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Gelteq	N/A	N/A	N/A

Summary

Biofrontera and Gelteq tied by winning 6 of the 12 factors compared between the two stocks.

How does Gelteq compare to ABVC BioPharma?

Gelteq (NASDAQ:GELS) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Gelteq and Gelteq both had 1 articles in the media. Gelteq's average media sentiment score of 0.00 equaled ABVC BioPharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gelteq	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gelteq has higher earnings, but lower revenue than ABVC BioPharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	87.63	-$4.30M	N/A	N/A
ABVC BioPharma	$510K	50.17	-$7.91M	-$0.30	N/A

Gelteq has a beta of -0.41, indicating that its stock price is 141% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

Gelteq's return on equity of 0.00% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
ABVC BioPharma	N/A	-47.68%	-30.97%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.4% of ABVC BioPharma shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Gelteq and ABVC BioPharma tied by winning 4 of the 8 factors compared between the two stocks.

How does Gelteq compare to Cocrystal Pharma?

Gelteq (NASDAQ:GELS) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Gelteq's return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Cocrystal Pharma	N/A	-207.47%	-123.33%

6.7% of Cocrystal Pharma shares are held by institutional investors. 39.4% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Gelteq has higher revenue and earnings than Cocrystal Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	87.63	-$4.30M	N/A	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A

In the previous week, Gelteq had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 1 mentions for Gelteq and 0 mentions for Cocrystal Pharma. Gelteq's average media sentiment score of 0.00 equaled Cocrystal Pharma'saverage media sentiment score.

Company	Overall Sentiment
Gelteq	Neutral
Cocrystal Pharma	Neutral

Gelteq has a beta of -0.41, indicating that its share price is 141% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

Summary

Gelteq beats Cocrystal Pharma on 5 of the 8 factors compared between the two stocks.

How does Gelteq compare to Plus Therapeutics?

Gelteq (NASDAQ:GELS) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Gelteq has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Gelteq's return on equity of 0.00% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Gelteq has higher revenue and earnings than Plus Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	87.63	-$4.30M	N/A	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

In the previous week, Gelteq and Gelteq both had 1 articles in the media. Gelteq's average media sentiment score of 0.00 equaled Plus Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gelteq	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.3% of Plus Therapeutics shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Gelteq has a beta of -0.41, meaning that its stock price is 141% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Plus Therapeutics has a consensus price target of $51.75, indicating a potential upside of 1,778.40%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Plus Therapeutics beats Gelteq on 6 of the 11 factors compared between the two stocks.

How does Gelteq compare to ?

Gelteq (NASDAQ:GELS) and (:) are related companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

has lower revenue, but higher earnings than Gelteq.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	87.63	-$4.30M	N/A	N/A
	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
	N/A	N/A	N/A

In the previous week, had 1423 more articles in the media than Gelteq. MarketBeat recorded 1424 mentions for and 1 mentions for Gelteq. Gelteq's average media sentiment score of 0.00 equaled 'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gelteq	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
	347 Very Positive mention(s)	336 Positive mention(s)	333 Neutral mention(s)	271 Negative mention(s)	137 Very Negative mention(s)	Neutral

Given 's higher probable upside, analysts plainly believe is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Gelteq and tied by winning 2 of the 4 factors compared between the two stocks.

Get Gelteq News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GELS vs. The Competition

Export

Metric	Gelteq	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.64M	$12.25B	$7.25B	$12.92B
Dividend Yield	N/A	2.58%	2.53%	9.14%
P/E Ratio	N/A	792.20	273.54	25.43
Price / Sales	87.63	754.62	630.11	96.68
Price / Cash	N/A	90.26	77.08	52.44
Price / Book	0.83	12.47	12.85	6.17
Net Income	-$4.30M	$2.83B	$3.49B	$350.08M
7 Day Performance	62.02%	4.03%	1.04%	-0.14%
1 Month Performance	59.55%	6.29%	5.52%	1.02%
1 Year Performance	-42.31%	9.93%	24.39%	14.51%

Gelteq Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GELS Gelteq	0.8118 of 5 stars	$0.90 +0.8%	N/A	-6.2%	$9.64M	$110K	N/A	N/A	Gap Down
BFRI Biofrontera	1.0903 of 5 stars	$1.59 +6.7%	N/A	+91.9%	$23.61M	$41.71M	N/A	70
ABVC ABVC BioPharma	0.3601 of 5 stars	$0.83 +4.3%	N/A	-64.7%	$22.12M	$510K	N/A	30	News Coverage Positive News Gap Up
COCP Cocrystal Pharma	1.1804 of 5 stars	$1.10 -3.5%	N/A	-22.6%	$21.19M	N/A	N/A	10	Positive News Gap Up
PSTV Plus Therapeutics	1.8456 of 5 stars	$3.05 -1.6%	$51.75 +1,596.7%	-73.5%	$21.00M	N/A	N/A	20	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GELS) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gelteq (GELS) Competitors

GELS vs. BFRI, ABVC, COCP, PSTV, and VYNE

How does Gelteq compare to Biofrontera?

Summary

How does Gelteq compare to ABVC BioPharma?

Summary

How does Gelteq compare to Cocrystal Pharma?

Summary

How does Gelteq compare to Plus Therapeutics?

Summary

How does Gelteq compare to ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gelteq (GELS) Competitors

GELS vs. BFRI, ABVC, COCP, PSTV, and VYNE

How does Gelteq compare to Biofrontera?

Which has better earnings & valuation, BFRI or GELS?

Which has more risk & volatility, BFRI or GELS?

Does the media favor BFRI or GELS?

Do analysts prefer BFRI or GELS?

Do institutionals & insiders have more ownership in BFRI or GELS?

Is BFRI or GELS more profitable?

Summary

How does Gelteq compare to ABVC BioPharma?

Does the media prefer GELS or ABVC?

Which has stronger earnings and valuation, GELS or ABVC?

Which has more volatility & risk, GELS or ABVC?

Is GELS or ABVC more profitable?

Do analysts prefer GELS or ABVC?

Do insiders & institutionals have more ownership in GELS or ABVC?

Summary

How does Gelteq compare to Cocrystal Pharma?

Do analysts rate GELS or COCP?

Is GELS or COCP more profitable?

Do institutionals and insiders have more ownership in GELS or COCP?

Which has better valuation and earnings, GELS or COCP?

Does the media prefer GELS or COCP?

Which has more volatility and risk, GELS or COCP?

Summary

How does Gelteq compare to Plus Therapeutics?

Is GELS or PSTV more profitable?

Which has better earnings and valuation, GELS or PSTV?

Does the media prefer GELS or PSTV?

Do institutionals and insiders hold more shares of GELS or PSTV?

Which has more volatility & risk, GELS or PSTV?

Do analysts rate GELS or PSTV?

Summary

How does Gelteq compare to ?

Which has higher valuation and earnings, GELS or ?

Is GELS or more profitable?

Does the media refer more to GELS or ?

Do analysts recommend GELS or ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools